Generation Bio Co.

NasdaqGS:GBIO Stock Report

Market Cap: US$36.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Generation Bio Balance Sheet Health

Financial Health criteria checks 4/6

Generation Bio has a total shareholder equity of $50.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $121.9M and $71.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$89.62m
EquityUS$50.56m
Total liabilitiesUS$71.34m
Total assetsUS$121.90m

Recent financial health updates

Analysis Article Nov 14

Companies Like Generation Bio (NASDAQ:GBIO) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article May 01

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Dec 07

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Jul 11

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Mar 11

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Recent updates

Analysis Article Nov 14

Companies Like Generation Bio (NASDAQ:GBIO) Could Be Quite Risky

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jul 14

There Is A Reason Generation Bio Co.'s (NASDAQ:GBIO) Price Is Undemanding

With a price-to-sales (or "P/S") ratio of 1.1x Generation Bio Co. ( NASDAQ:GBIO ) may be sending very bullish signals...
Analysis Article Mar 16

Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29%

Unfortunately for some shareholders, the Generation Bio Co. ( NASDAQ:GBIO ) share price has dived 29% in the last...
Analysis Article May 01

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Dec 07

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Jul 11

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Mar 11

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Nov 19

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article Aug 05

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha Aug 04

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Generation Bio press release (NASDAQ:GBIO): Q2 GAAP EPS of -$0.66 misses by $0.04. The company believes that its cash position of $312.2M will fund its operating plan into 2025. “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “This quarter, process development and scaling of rapid enzymatic synthesis (RES) for production of our closed-ended DNA (ceDNA) construct has allowed us to pursue a more flexible and capital efficient manufacturing strategy. In the remainder of the year, we plan to continue to develop our unique cell-targeted lipid nanoparticle (ctLNP) system for systemic delivery to hepatocytes, as well as for other therapeutic areas such as the retina and vaccines.”
Analysis Article Apr 20

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha Dec 30

Generation Bio: High-Risk, Medium-To-Low-Reward

Generation Bio is a preclinical-stage gene therapy company aiming to use non-viral delivery system to deliver DNA in vivo. The non-viral delivery system of choice is lipid nanoparticle, similar delivery vehicle the mRNA COVID vaccines are using. The big issue is, LNP will not help with nuclear translocation which is needed for DNA gene therapy to have decent efficacy. The recent preclinical update on their Hemophilia A program confirms the low efficacy issue of LNP-DNA, and therefore the stock is not a buy.
Analysis Article Nov 11

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Jul 28

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article Mar 08

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jan 14

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Potential Generation Bio Co. ( NASDAQ:GBIO ) shareholders may wish to note that the Independent Director, Charles...
Analysis Article Dec 27

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

Financial Position Analysis

Short Term Liabilities: GBIO's short term assets ($93.5M) exceed its short term liabilities ($21.0M).

Long Term Liabilities: GBIO's short term assets ($93.5M) exceed its long term liabilities ($50.3M).


Debt to Equity History and Analysis

Debt Level: GBIO is debt free.

Reducing Debt: GBIO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GBIO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GBIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.1% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/10 14:52
End of Day Share Price 2026/02/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Generation Bio Co. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Silvan TuerkcanCitizens JMP Securities, LLC
Brendan SmithTD Cowen
Raju PrasadWilliam Blair & Company L.L.C.